Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations-Reference-Cited by-同舟云学术

Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations

Published:2021-08-20 Issue:3 Volume:189 Page:641-651
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Xu Jing,Keenan Tanya E.,Overmoyer Beth,Tung Nadine M.,Gelman Rebecca S.,Habin Karleen,Garber Judy E.,Ellisen Leif W.,Winer Eric P.,Goss Paul E.,Yeap Beow Y.,Chabner Bruce A.^ORCID,Isakoff Steven J.

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-021-06292-7.pdf

Reference39 articles.

1. Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124:31–42. https://doi.org/10.1007/s00439-008-0529-1

2. Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG, Chenevix-Trench G, Rahman N, Robson M, Domchek SM, Foulkes WD (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372:2243–2257. https://doi.org/10.1056/NEJMsr1501341

3. Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R, Pillai S, Lam AK, Gopalan V (2019) Hereditary breast cancer; Genetic penetrance and current status with BRCA. J Cell Physiol 234:5741–5750. https://doi.org/10.1002/jcp.27464

4. Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, Katagiri T, Yoshida T, Nakamura S, Sugano K, Miki Y, Hirata M, Matsuda K, Spurdle AB, Kubo M (2018) Germline pathogenic variants of 11 breast cancer genes in 7051 Japanese patients and 11,241 controls. Nat Commun 9:4083. https://doi.org/10.1038/s41467-018-06581-8

5. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333. https://doi.org/10.1200/JCO.2006.09.1066

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches;Cancers;2023-07-16

2. PARP inhibitors: enhancing efficacy through rational combinations;British Journal of Cancer;2023-07-10

3. Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07

4. Immunotherapy in glioblastoma treatment: Current state and future prospects;World Journal of Clinical Oncology;2023-04-24

5. Statistical mining of triple-negative breast cancer-specific nanobodies among huge libraries from immunized alpacas;2023-03-31